Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
UCB Sa
of Belgium
(2018
sales of 4.63 billion Euro [US$5.10 billion]
of which 31%
was Cimzia),
Protek PAO
of Russia
(251.73 billion Russian Rubles [US$3.91 billion]
of which 72%
was Distribution), and
Lonza Group AG
which is
based in Switzerland
(5.54 billion Swiss Francs [US$5.60 billion]
of which 56%
was Pharma&Biotech).
Sales Analysis.
Grifols SA reported sales of 4.49 billion Euro (US$4.94 billion)
for the
year ending
December of 2018.
This
represents
an
increase of 3.9%
versus 2017, when the company's sales were 4.32 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2013, sales have increased a total of 64%).
Sales of Bio Supplies saw an increase
that was more than double the company's growth rate: sales were up
150.0% in 2018, from
66.79 million Euro to 167.00 million Euro.
Grifols SA also saw significant increases in sales in
Hospital (up 19.3% to 119.45 million Euro)
and
Others/raw Materials (up 22.9% to 22.45 million Euro)
.
Not all segments of Grifols SA experienced an increase in sales in 2018:
sales of Diagnostics fell 0.1% to 702.27 million Euro.